Lipid nanoparticles engineered to target therapeutic RNA to the pancreas

Posted on
lipid-nanoparticles-engineered-to-target-therapeutic-rna-to-the-pancreas
Lipid nanoparticles engineered to target therapeutic RNA to the pancreas
  • NEWS AND VIEWS

A two-pronged strategy directs drug-delivering nanoparticles to the pancreas — and shows promise in animal models of serious pancreatic diseases.

By

  1. Aviad Elisha

    1. Aviad Elisha is at the Shmunis School of Biomedicine and Cancer Research, Tel Aviv University, Tel Aviv, Israel, and in the Department of Materials Sciences and Engineering, the Center for Nanoscience and Nanotechnology and the Cancer Biology Research Center, Tel Aviv University.

  2. Dan Peer

    1. Dan Peer is at the Shmunis School of Biomedicine and Cancer Research, Tel Aviv University, Tel Aviv, Israel, and in the Department of Materials Sciences and Engineering, the Center for Nanoscience and Nanotechnology and the Cancer Biology Research Center, Tel Aviv University.

The clinical use of lipid nanoparticles (LNPs) for drug delivery is currently limited by their tendency to accumulate in the liver. Tuning their biodistribution to reach other tissues and to target specific cell types in an organ remains a major challenge1,2. Writing in Nature, Lei et al.3 report their approach for engineering LNPs that specifically deliver therapeutic RNA to the pancreas — successfully targeting cell populations that were previously beyond the reach of LNPs, and unlocking avenues of research towards therapies that combat currently incurable pancreatic diseases.

Access options

Access Nature and 54 other Nature Portfolio journals

Get Nature+, our best-value online-access subscription

$32.99 / 30 days

cancel any time

Subscribe to this journal

Receive 51 print issues and online access

$199.00 per year

only $3.90 per issue

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

doi: https://doi.org/10.1038/d41586-026-00294-5

References

  1. Peer, D. et al. Nature Nanotechnol. 2, 751–760 (2007).

    Article  Google Scholar 

  2. Kon, E., Ad-El, N., Hazan-Halevy, I., Stotsky-Oterin, L. & Peer, D. Nature Rev. Clin. Oncol. 20, 739–754 (2023).

    Article  Google Scholar 

  3. Lei, J. et al. Nature https://doi.org/10.1038/s41586-026-10158-7 (2026).

    Article  Google Scholar 

  4. Wang, X. et al. Nature Protoc. 18, 265–291 (2023).

    Article  PubMed  Google Scholar 

  5. Chan, W. C. W. BME Front. 4, 0016 (2023).

    Article  PubMed  Google Scholar 

  6. Hamilton, A. G. et al. ACS Nano. 18, 16151–16165 (2024).

    Article  PubMed  Google Scholar 

  7. Rampado, R. et al. Adv. Sci. 12, e2408744 (2025).

    Article  Google Scholar 

  8. Tarab-Ravski, D. et al. J. Control Release 376, 286–302 (2024).

    Article  PubMed  Google Scholar 

  9. Lam, K. et al. Adv. Mater. 35, e2211420 (2023).

    Article  PubMed  Google Scholar 

Download references

Competing Interests

D. P. receives unrelated licensing fees (to patents on which he was an inventor) from, has invested in, consults for (or is on scientific advisory boards or boards of directors for), has lectured for (and received a fee) and conducts sponsored research at Tel Aviv University for: ART Biosciences; BioNtech SE; Earli Inc.; Kernal Biologics; LAND Therapeutics; Merck KGaA; Newphase Ltd.; NeoVac Ltd.; RiboX Therapeutics; Roche; SirTLabs Corporation; Teva Pharmaceuticals Inc.

Subjects

Latest on:

Related Posts